⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15251406 | 0.78 | — | — | |
| SCHEMBL13077993 | 0.78 | — | — | |
| SCHEMBL472649 | 0.78 | — | — | |
| SCHEMBL336970 | 0.76 | — | — | |
| Bromide SCHEMBL3971655 | 0.76 | GANAB (0.30) | — | |
| SCHEMBL336761 | 0.76 | — | — | |
| SCHEMBL294661 | 0.76 | — | — | |
| SCHEMBL23058736 | 0.76 | GANAB (0.36) | — | |
| SCHEMBL294003 | 0.76 | GANAB (0.36) | — | |
| SCHEMBL8069756 | 0.76 | GANAB (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226313-A1 | CEACAM5 ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | SEAGEN INC. | 2024-07-11 | — | — | US | disclosed |
| US-20230270871-A1 | MARKERS FOR USE IN METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) | AGENSYS, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230038373-A1 | STABILE CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2023-02-09 | — | — | US | disclosed |
| US-11548984-B2 | Light- or heat-curing method and curable resin composition | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| US-20230001005-A1 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| CN-110678500-B | Photo-or thermosetting method and curable resin composition | 富士胶片和光纯药株式会社 | 2022-10-14 | — | — | CN | disclosed |
| US-11331394-B2 | CD19 binding agents and uses thereof | SEAGEN INC. (US) | 2022-05-17 | — | — | US | disclosed |
| CN-108602955-B | Photocuring method, compound used in photocuring method, and composition | 富士胶片和光纯药株式会社 | 2021-08-06 | — | — | CN | disclosed |
| WO-2021067861-A1 | CAMPTOTHECIN PEPTIDE CONJUGATES | SEAGEN INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20200399242-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-12-24 | — | — | US | disclosed |
| US-20120328546-A1 | Paxillin Stimulating Compositions and Cosmetic Uses Thereof | AVON PRODUCTS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120315686-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-8288352-B2 | Auristatins having an aminobenzoic acid unit at the N terminus | SEATTLE GENETICS, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8168212-B2 | Topical compositions comprising non-proteogenic amino acids and methods of treating skin | AVON PRODUCTS, INC (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110151029-A1 | Paxillin Stimulating Compositions and Cosmetic Uses Thereof | AVON PRODUCTS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| US-20100261769-A1 | Topical Compositions Comprising Non-Proteogenic Amino Acids and Methods of Treating Skin | AVON PRODUCTS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7560106-B2 | Rationally designed heparinases derived from heparinase I and II and methods of sequencing therewith | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-07-14 | — | — | US | disclosed |
| WO-2009051399-A2 | NOVEL COMPOUNDS OF REVERSE TURN MIMETICS AND THE USE THEREOF (1) | CHOONGWAE PHARMA CORPORATION (KR) | 2009-04-23 | — | — | WO | disclosed |
| US-20080300192-A1 | Auristatins Having an Aminobenzoic Acid Unit at the N Terminus | SEATTLE GENETICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20070148158-A1 | Rationally designed heparinases derived from heparinase II | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-06-28 | — | — | US | disclosed |